PT  - JOURNAL ARTICLE
AU  - Buckley, Rita
ED  - Perin, Emerson
TI  - Neutral Outcomes but Important Insights from FOCUS-CCTRN
DP  - 2012 Jun 01
TA  - MD Conference Express
PG  - 22--22
VI  - 12
IP  - 4
4099  - http://mdc.sagepub.com/content/12/4/22.short
4100  - http://mdc.sagepub.com/content/12/4/22.full
AB  - Cell therapy has emerged as an exciting and innovative approach for treating patients with advanced ischemic heart disease, including those with refractory angina and/or heart failure [Perin EC et al. JAMA 2012]. The FOCUS-CCTRN trial [NCT00824005] was designed to evaluate the safety and efficacy of bone marrow mononuclear cells in patients with chronic ischemic heart disease and left ventricular dysfunction with no other revascularization options.